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Abstract
Buruli Ulcer (BU) is a neglected infectious disease caused byMycobacterium ulcerans that
is responsible for severe necrotizing cutaneous lesions that may be associated with bone
involvement. Clinical presentations of BU lesions are classically classified as papules, nod-
ules, plaques and edematous infiltration, ulcer or osteomyelitis. Within these different clini-
cal forms, lesions can be further classified as severe forms based on focality (multiple
lesions), lesions’ size (>15cm diameter) or WHO Category (WHO Category 3 lesions).
There are studies reporting an association between delay in seeking medical care and the
development of ulcerative forms of BU or osteomyelitis, but the effect of time-delay on the
emergence of lesions classified as severe has not been addressed. To address both issues,
and in a cohort of laboratory-confirmed BU cases, 476 patients from a medical center in
Allada, Benin, were studied. In this laboratory-confirmed cohort, we validated previous
observations, demonstrating that time-delay is statistically related to the clinical form of BU.
Indeed, for non-ulcerated forms (nodule, edema, and plaque) the median time-delay was
32.5 days (IQR 30.0–67.5), while for ulcerated forms it was 60 days (IQR 20.0–120.0) (p =
0.009), and for bone lesions, 365 days (IQR 228.0–548.0). On the other hand, we show
here that time-delay is not associated with the more severe phenotypes of BU, such as
multi-focal lesions (median 90 days; IQR 56–217.5; p = 0.09), larger lesions (diameter
>15cm) (median 60 days; IQR 30–120; p = 0.92) or category 3 WHO classification (median
60 days; IQR 30–150; p = 0.20), when compared with unifocal (median 60 days; IQR 30–
90), small lesions (diameter15cm) (median 60 days; IQR 30–90), or WHO category 1+2
lesions (median 60 days; IQR 30–90), respectively. Our results demonstrate that after an
initial period of progression towards ulceration or bone involvement, BU lesions become
stable regarding size and focal/multi-focal progression. Therefore, in future studies on BU
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Author Summary
Buruli Ulcer (BU) is a neglected disease caused byMycobacterium ulcerans. Clinical pre-
sentations of BU lesions are classically classified as papules, nodules, plaques and edema-
tous infiltration, ulcer or osteomyelitis. Within these different clinical forms, lesions can
be further classified as severe forms based on focality (multiple lesions), lesions’ size
(>15cm diameter) or WHO Category (WHO Category 3 lesions). There are studies
reporting an association between delay in seeking medical care and the development of
ulcerative forms of BU or osteomyelitis, but the effect of time-delay on the emergence of
lesions classified as severe has not been addressed. To address both issues, and in a cohort
of laboratory-confirmed BU cases, 476 patients from a medical center in Allada, Benin,
were studied. In our cohort, we validated previous observations, demonstrating that time-
delay is statistically related to the clinical form of BU, namely ulcers and osteomyelitis.
However, time-delay is not related with more severe phenotypes, implying that severe clin-
ical forms of BU should be considered as distinct phenotypes of the same disease and sub-
jected to specific risk factor investigation.
Introduction
Buruli ulcer (BU), caused byMycobacterium ulcerans, is the third most common mycobacter-
iosis worldwide, after tuberculosis and leprosy [1]. BU pathogenesis is mediated by mycolac-
tone, a potent polyketide-derived macrolide that triggers apoptotic cell death [2] and is
associated with the necrotic nature of the disease [3]. BU mostly affects people in tropical coun-
tries in Africa [4], America [5], Asia [6] and Australia [7]. Although no official estimate of
global incidence is available at present, West Africa is the main endemic area, with 1967 new
cases reported by Côte d'Ivoire, Ghana, and Benin in 2013[8]. BU is a devastating necrotising
skin infection characterised by pre-ulcerative lesions (papules, nodules, plaques and edematous
infiltration), which commonly develop into ulcers with undermined edges and can spread to
an entire limb [9] and can also affect the bone (osteomyelitis) [10]. Moreover, within these clin-
ical presentations, more aggressive severe forms of BU, such as multiple lesions, larger lesions
or higher World Health Organization (WHO) categories have been described [11], although
underreported and less understood. Epidemiological studies onM. ulcerans transmission, on
BU risk factors and on the host immune status, suggest that the variable frequency of BU and
its distinct clinical forms are related to: i) age; ii) gender; iii) preferential anatomical site; iv)
water contact; and v) regional occurrences [12,13,14,15,16].
To date, a reduced number of risk factors underlying the severe BU phenotypes had been
reported. HIV co-infection is one of the few examples. Some studies revealed an increased BU
prevalence among HIV patients, especially those presenting large lesions and osteomyelitis
[17,18]. Specifically, low CD4 cell counts were significantly associated with larger lesions and
patients with a CD4 cell count below 500 cell/mm3 took twice as long to recover from BU
when compared with individuals with a normal CD4 cell count [19]. Other risk factors, such as
hypoproteinemia [11] and anemia [20] were also identified to be associated with severe forms
of BU disease.
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In addition, the delay in seeking medical care and the late medical diagnosis of BU have
been proposed to account for the disease presentation [21,22,23,24]. In fact, in BU endemic
regions the culture and beliefs are powerful factors that affect proper medical intervention, as
patients preferentially seek treatment from traditional practitioners, or herbalists [22]. On top
of this, the lack of knowledge on the available treatments and their effectiveness, the financial
constraints during hospitalisation, fear of treatment, and poor access to health facilities are also
important aspects delaying the pursuit of proper treatment [25,26]. Indeed, delay in seeking
medical care has been previously associated with the distinct BU clinical forms. Taking into
consideration that the time from progression of a pre-ulcer to an ulcer is variable and can
range from a few weeks to several months (e.g. estimated average time of 30–90 days) [27], it
was established that individuals with non-ulcerated forms had a median delay of 30 to 45 days,
while individuals with ulcers presented a 60-day delay and patients with osteomyelitis up to 90
days [28]. Thus, the more advanced and destructive ulcerated forms and osteomyelitis are asso-
ciated with longer delay-periods, while non-ulcerated forms are more common in patients
with recent infection [28], justifying the importance of early diagnosis and treatment for the
disease.
Nonetheless, more aggressive, severe clinical presentations of BU, such as large lesions
(>15cm in diameter) and multifocal lesions, have also been described [11], although the
underlying pathological mechanisms are yet unclear [29]. While this can be associated with
characteristics of the patient itself (genetic susceptibility/health status) or with the virulence of
the infecting strain, it is also rational to question the influence of the delay in health seeking on
the appearance of the more severe forms of BU. To our knowledge, the latter aspect is yet to be
studied. Therefore, to uncover whether the time-lapse between the first remembered symptoms
and clinical diagnosis is associated to disease severity, we retrospectively analysed a cohort of
476 laboratory-confirmed BU treated cases discovered in a highly endemic area in Allada,
Benin, between 2005 and 2013.
Materials and Methods
Ethics statement
Ethical approval (clearance Nu 018, 20/OCT/2011) for integrating studies on BU was obtained
from the National Ethical Review Board of the Ministry of Health in Benin, registered under
the Number IRB0006860. The Centre de Dépistage et de Traitement de l'Ulcère de Buruli
(CDTUB)—Allada and the national BU control program authorities approved access to the
registry. All data analyzed in this study was anonymized.
Study setting, participants and design
We retrospectively collected clinical data from 476 laboratory-confirmed BU patients of
CDTUB in Allada, Benin—between January 2005 and December 2013. At the moment of diag-
nosis, parameters such as age, gender, major clinical form (nodule, plaque, edema, ulcer or
osteomyelitis) and multifocal presentations were registered. For mixed clinical forms, the most
severe lesion was considered the major clinical form. Additionally, lesion size (cm, considering
major diameter), WHO category [30] (Category 1: maximum lesion diameter<5cm; Category
2: maximum lesion diameter 5–15cm; and Category 3: minimum lesion diameter>15cm asso-
ciated or not with osteomyelitis and/or multifocal lesions and/or at a critical site), lesion site
(upper or lower limb, trunk, head and/or neck) and laboratory confirmation tests (culture of
M. ulcerans from the lesion, histopathology with the presence of acid-fast bacilli, or highly spe-
cific IS2404 real-time PCR) were taken into consideration. The HIV status was also retained
for the present study and excluded from analysis if positive.
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Delay in seeking medical care (time between first symptoms or signs remembered and med-
ical attendance) was also recorded. The time of seeking medical care was defined as the
moment of diagnosis and treatment initiation. All included patients completed antibiotherapy
according to the WHO recommendations and were treated with surgical procedures [30].
Statistical analysis
Explanatory and descriptive analysis of the study cohort was performed based on the following
variables: age at the moment of the BU diagnosis; gender; clinical form (ulcer, plaque, edema,
nodule and osteomyelitis); lesion site; and lesion severity. Severe phenotypes were defined as
multifocal lesions (more than one lesion); large lesions (diameter>15cm) or Category 3 lesions
(minimum lesion diameter>15cm associated or not with osteomyelitis,multifocal lesions and/
or at a critical site) as classified by the WHO recommendations. Median comparisons were per-
formed through one-way ANOVA’s (Brown-Forsythe andWelch, when applicable) using age,
gender, site of lesion, clinical BU form; and lesion severity as explanatory variables and time-
delay seeking medical care (days, using means and medians distribution in each group) as a
dependent variable. Unadjusted and adjusted (for age-cutoff value 15 years of age- and gender
binary or linear logistic regression models) odds ratios were then calculated to explore the
effects of time-delay in diagnosis into the clinical form of BU lesions, and particularly into
severe phenotypes of BU. We systematically fit the model, controlling age (dichotomized or
ordinal) and gender with the considered time-delay (to seek medical attendance) as explana-
tory variables for each of the clinical lesions and severe phenotypes defined for BU. All the




The BU cohort (CDTUB, Allada, Benin), comprising 476 cases, had laboratory BU confirma-
tion by at least one laboratory diagnostic test, as recommended by the WHO. Results were pos-
itive for IS2404 RT-PCR in 430 (90.3%) cases and Ziehl-Neelsen staining in 327 (68.7%) cases.
All cases were HIV negative. The median age at diagnosis was 12 years (IQR: 7–24 years; mean
17.9 ± 16.3 years), with 321 (67.4%) patients 15 years old or under. Although the overall gender
ratio of the patients was balanced (245 [51.5%] male) (Table 1), a major distortion of this ratio
was recorded as a function of age, with males being predominant in younger patients and
females in older patients (OR 2.99, 95%CI 2.00–4.46, p = 0.0001). Specifically, male patients
accounted for 193 (60.1%) of the patients younger than 15, but only 52 (33.5%) of those were
over 15 (Table 1).
Considering the dominant clinical BU form per patient, 4 (0.8%) presented nodules (Fig 1A
and 1F and Table 1), 24 (5.0%) presented edema (Fig 1B and 1F and Table 1), 125 (26.3%) pre-
sented plaques (Fig 1C and 1F and Table 1), and 320 (67.2%) presented ulcers (Fig 1E and 1F
and Table 1). Osteomyelitis was diagnosed in 5 patients (1.1%), and was considered the most
relevant form in 3 of the patients (0.6%) (Fig 1E and 1F and Table 1). Concerning the site of
lesions, 256 (53.8%) patients presented lesions on the lower limbs, while 171 (35.9%) had
lesions on the upper limbs (Fig 2 and Table 1). Atypical sites (head, neck and/or trunk)
accounted for 49 (10.3%) patients (Fig 2 and Table 1). Site of the lesion and relative age, gender
and dominant clinical form distribution are represented in Fig 2.
Regarding the observed severe forms of BU, 22 (4.6%) patients presented lesions in more
than one localization (Fig 3A and Table 1), while 142 (29.8%) patients presented lesions larger
than 15cm in major diameter (Fig 3B and Table 1). The WHO category 3 is a broader
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classification given that it comprises patients with multiple lesions, lesions with a diameter
>15cm associated or not with osteomyelitis and/or lesions at a critical site. Taking into account
these criteria, we recorded 315 (66.2%) patients in category 1+2 and 161 (33.8%) in category 3
(Fig 3C and Table 1).
The different clinical presentations, as well as the severe forms of these lesions, were sub-
jected to age and gender adjustments (Tables 2 and 3, respectively). No significant interference
was recorded in the binary logistic regression, except for upper body lesions (upper limb, head
or neck), for which there was an overrepresentation of younger ages (OR 0.986, 95%CI 0.974–
0.998, p = 0.018) (Table 2).
Table 1. Age and gender distribution according to lesion location, lesion phenotype, and lesion severity in 476 laboratory-confirmed BU treated
patients at CDTUB—Allada from 2005 to 2013.
Patient n (%) Age distribution (>15 | 15) Gender distribution (F|M)
Gender
Male 245 (51.5%) 52 | 193 ..
Female 231 (48.5%) 103 | 128 ..
Age
> 15 years old 155 (32.6%) .. 103 | 52
 15 years old 321 (67.4%) .. 128 | 193
Lesion location a
Head and neck 6 (1.3%) 2 | 4 4 | 2
Thorax and abdomen 43 (9.0%) 9 | 34 18 | 25
Upper Limb 171 (35.9%) 51 | 120 88 | 83
Lower Limb 256 (53.8%) 93 | 163 121 | 135
Lower limb lesions vs. Upper limb lesions 256 (53.8%) 93 | 163 121 | 135
220 (46.2%) 62 | 158 110 | 110
Clinical lesion
Nodule a 4 (0.8%) 0 | 4 3 | 1
Edema a 24 (5.0%) 4 | 20 10 | 14
Plaque a 125 (26.3%) 44 | 81 62 | 63
Ulcer a 320 (67.2%) 105 | 215 155 | 165
Ostemyelitis a 3 (0.6%) 2 | 1 1 | 3
All 476 (100%) 155 | 321 231 | 245
Non-ulcerative vs. Ulcerative forms 156 (32.8%) 49 | 107 77 | 82
320 (67.2%) 105 | 215 155 | 165
Edema vs. Other non-ulcerated forms 24 (5.0%) 4 | 20 10 | 14
129 (27.1%) 44 | 85 65 | 64
Multifocal lesions
Multifocal 22 (4.6%) 8 | 14 10 | 12
Unifocal 454 (95.4%) 147 | 307 221 | 233
Lesion size
> 15cm 142 (29.8%) 47 | 95 62 | 80
 15cm 334 (70.2%) 108 | 226 169 | 165
WHO Category
Category 3 161 (33.8%) 55 | 106 71 | 90
Category 1 + 2 315 (66.2%) 100 | 215 160 | 155
a dominant clinical form
doi:10.1371/journal.pntd.0004005.t001
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Time-delay to seek medical care
The overall mean time-delay to seek medical care was 101.1 days (95%CI 86.3–117.0) (S1
Table). Since the variable time-delay does not follow a normal distribution (Kurtosis = 48.2;
Skewness = 6.4), median variations were considered to compare the distinct behavior of depen-
dent variables. Time-delay to seek medical care was indistinct for male and female gender
(p = 0.538) (Fig 4A and S1 Table): median was 60 days [IQR 30–90] for both genders. How-
ever, age was associated with significantly different delay times (p = 0.004) (Fig 4B and S1
Table). Median was 60 days [IQR 30–120] for patients over 15 years old at the moment of the
diagnosis; while time-delay was 45 days [IQR 30–90] for patients with 15 years of age or under.
Time-delay was also related to the clinical form of the disease (Fig 5). Median was 32.5 days
[IQR 30–67.5] for non-ulcerated forms (nodule, edema, and plaque); 60 days [IQR 20.0–120.0]
for ulcerated forms; and 365 days [IQR 228–548] for bone lesions. When the time-delay
among patients with non-ulcerated versus ulcerated forms was compared, we confirmed signif-
icant discrepancies (p = 0.009) (Fig 5B and S1 Table). In addition, among the non-ulcerated
clinical forms, edema was significantly associated with longer time-delays when compared
with others non-ulcerated forms (median 45 days, IQR 30–105 versus 30 days, IQR 30–60,
respectively, with p = 0.03) (S1 Table). Even when age and gender were adjusted in binary
logistic regression, we observed an increased risk of developing ulcerative lesions as each day/
month passed (Table 4).
Considering severe forms of BU, none of the aggressive phenotypes were considered related
to significantly different delay times to seek medical care: multifocal lesions (median 90 days,
IQR 56.3–217.5, p = 0.09) (Fig 6A and S2 Table), larger lesions with diameter>15cm (median
Fig 1. Prevalence of clinical BU lesions.Representative images of (A) nodule, (B) edema, (C) plaque, (D) ulcer, (E) osteomyelitis and (F) the percentage of
each clinical presentation.
doi:10.1371/journal.pntd.0004005.g001
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60 days, IQR 30–120, p = 0.92) (Fig 6B and S2 Table) or category 3 WHO classification
(median 60 days, IQR 30–150, p = 0.20) (Fig 6C and S2 Table), when compared with unifocal
(median 60 days, IQR: 30–90), small lesions (diameter15cm) (median 60 days, IQR 30–90)
or WHO category 1+2 lesions (median 60 days, IQR 30–90), respectively (Fig 6A–6C and S2
Fig 2. Age, gender, clinical BU lesion, and lesion location. Age (15 years old, >15 years old), gender, and clinical BU forms according to lesion
distribution throughout the three major areas of the body (lower limbs, upper limbs, and head+trunk).
doi:10.1371/journal.pntd.0004005.g002
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Table). Finally, when systematically fit within binary (dichotomized variables) (Table 5) or lin-
ear (Table 6) logistic regression models controlling for age and gender, time-delay to seek med-
ical care remained statistically insignificant with respect to the occurrence of the most
aggressive severe clinical forms.
Discussion
BU pathogenesis is related with necrosis of the subcutaneous tissue associated with mycolac-
tone, the potent cytotoxic/immunosuppressive toxin produced byM. ulcerans [3]. Initial pre-
ulcerative lesions (papules, nodules, plaques and edematous infiltration) can evolve into ulcers
and progressively spread over significant extensions of the body [9] or even affect the bone
[10]. Large national studies in West African countries, namely Ghana [31], Benin [28,29,32]
and Côte D`Ivoire [33], included the largest BU cohorts studied thus far and provided informa-
tion about the age and gender of patients, site of lesions and the major clinical forms—provid-
ing further clues on the evolution of BU pathology. The majority of these studies used distinct
methodologies (retrospective and/or prospective cohorts; cross-sectional) and a descriptive
approach, with a large proportion of diagnoses being retrospective and scar-based. Here, we
strictly consider laboratory-confirmed BU patients.
Concerning the BU clinical forms (papules, nodules, plaques, edematous infiltration, ulcers
and osteomyelitis), the observations of our study globally fit the variances reported in those
larger cohorts. Specifically, we confirm that BU is mainly a paediatric disease (median age of
diagnosis 12 years with IQR: 7–24 years and mean of 19.7 years); with a predominance of
lesions on the lower limbs (53.8%); a predominance of ulcerative forms (67.2%); and with an
equilibrium between genders. In addition, there is a distinct distribution of gender when age is
considered, with males being overrepresented in younger patients, reproducing data from pre-
vious studies [15,29].
Fig 3. Prevalence of severe BU lesions.Representative images of (A) multifocal lesions, (B) large lesions (>15cm), (C) WHOCategory 3 lesions, and the
percentage of each clinical presentation.
doi:10.1371/journal.pntd.0004005.g003
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Osteomyelitis and edematous forms are classified as belonging to the spectrum of BU pre-
sentations, although some authors consider them to be more severe clinical forms
[32,34,35,36]. Regarding osteomyelitis, a great variance in prevalence is described and further
complexity is added when suspected non-confirmed cases of bone involvement are included in
the analysis. Indeed, reported prevalence values of bone disease related to BU were as high as
29.5% [37] and 36.1% [38]. However, when only confirmed osteomyelitis cases were consid-
ered, prevalence decreased with values ranging between 6% [29] and 20% [39] in Africa and
Table 2. Univariate analysis of the effect of age and gender on clinical BU forms and lesion location in
476 laboratory-confirmed BU treated patients at CDTUB—Allada from 2005 to 2013 (binary logistic
regression).
Coeff. (SE) Odds Ratio (CI) p-value
Male
Age 0.006 0.972 (0.960–0.984) 0.0001
Upper body lesions a
Age 0.006 0.986 (0.974–0.998) 0.018
Gender 0.200 0.811 (0.559–1.177) 0.271
Nodule b
Age 0.105 0.867 (0.706–1.065) 0.174
Gender 1.164 0.218 (0.022–2.135) 0.191
Plaque b
Age 0.006 1.003 (0.991–1.016) 0.624
Gender 0.213 0.965 (0.635–1.465) 0.866
Edema b
Age 0.020 0.970 (0.933–1.008) 0.116
Gender 0.433 1.136 (0.486–2.654) 0.768
Ulcer b
Age 0.006 1.004 (0.992–1.016) 0.534
Gender 0.200 1.039 (0.702–1.537) 0.850
Osteomyelitis b
Age 0.042 0.972 (0.896–1.055) 0.501
Gender 0.934 1.220 (0.196–7.603) 0.831
a upper body lesions: head + neck + upper limbs + thorax + abdomen
b dominant clinical form
doi:10.1371/journal.pntd.0004005.t002
Table 3. Univariate analysis of the effect of age and gender on severe BU forms in 476 laboratory-con-
firmed BU treated patients at CDTUB—Allada from 2005 to 2013 (binary logistic regression).
Coeff. (SE) Odds Ratio (CI) p-value
Multifocal lesions
Age 0.012 1.010 (0.986–1.035) 0.433
Gender 0.450 1.224 (0.507–2.956) 0.653
Larger lesions (>15cm)
Age 0.006 1.004 (0.992–1.017) 0.489
Gender 0.207 1.363 (0.909–2.043) 0.134
WHO category 3
Age 0.006 1.004 (0.992–1.016) 0.550
Gender 0.200 1.342 (0.908–1.985) 0.140
doi:10.1371/journal.pntd.0004005.t003
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only 1% in Australia [40]. Moreover, HIV infection seems to favour the occurrence of osteomy-
elitis [17]. In the present study, osteomyelitis lesions only occurred in 1.1% of the at-risk popu-
lation, which could be related to the fulfillment of confirmed diagnosis criteria (e.g. x-ray or
surgical evidence) and the absence of the HIV co-infection selection criteria.
Eedematous lesions manifest as diffuse, extensive, usually non-pitting swelling with ill-
defined margins involving part or all of a limb or other part of the body [41]. Cases of edema-
tousM. ulcerans infection can be misdiagnosed as bacterial cellulitis leading to delays in diag-
nosis, progression of disease, increased morbidity and increased complexity and cost of
treatment. Additionally, edema is often self-perceived as not being a relevant health problem,
therefore delaying seeking medical attention. In previous studies, prevalence was determined
to be between 2.5% [42] and 12.5% [31]. In our study, edematous forms accounted for 5% of
the studied population, fitting with the prevalence reported in similar cohorts [31,34,35,36,42].
Fig 4. Time-delay to seekmedical care related to gender and age. Time-delay to seek medical care
related to (A) gender and (B) age. Circles represent the outliers and asterisks represent the extreme outliers.
Statistical significance was calculated usingWelch's t-test. Differences with a p-value of0.05 were
considered significant.
doi:10.1371/journal.pntd.0004005.g004
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Within to the above described clinical BU presentations, more aggressive, severe clinical pre-
sentations have been described [11], although the underlying pathological mechanisms are yet
unclear [29]. In our study, within the severe phenotypes, 33.8% of the patients were inWHO
category 3; 4.5% presented multifocal forms; and 29.8% of the patients presented lesions>15cm
in major diameter. Regarding multifocal lesions, previous studies describe highly variable preva-
lences (e.g. 2.0% -11.1%) [40,42,43,44,45,46]. Moreover, in our African cohort, we verify that
age does not associate with multifocal lesions, conversely to an Australian cohort [40]. Regard-
ing lesion size, only a few studies report large lesions as a specified studied variable, since these
lesions are usually included in category 3 lesions. However, when considered separately, their
prevalence ranged between 11.1% [47] and 36.0% [29], while category 3 lesions have been
reported to range between 19.7% [48] and 60.0% [39]–values replicated in the present study.
Fig 5. Time-delay to seekmedical care related to clinical BU forms. Time-delay to seek medical care
related to (A) clinical form N—nodule; P—plaque; E—edema; U—ulcer; O—osteomyelitis and (B) non-
ulcerative vs. ulcerative lesions. Circles represent the outliers and asterisks represent the extreme outliers.
Statistical significance was calculated usingWelch's t-test. Differences with a p-value of0.05 were
considered significant.
doi:10.1371/journal.pntd.0004005.g005
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The effect of time-delay in seeking medical care for BU patients is a relevant issue for public
health and patient management. Our observations in a cohort of laboratory-confirmed cases of
BU show that gender was not related with distinct behavior in seeking specific medical care
and that younger patients, mainly through their parents/legal tutors, spent less time seeking
medical attention prior to diagnosis (median 45 versus 60 days, for the group15 years old
versus>15 years old respectively, p = 0.004). In line with previous African studies, we found
that more advanced ulcerative forms were related to the delay in seeking medical care. Remark-
ably, and contrary to what one would expect, we found that multifocal lesions, larger lesions or
WHO category 3 lesions may be considered distinct clinical entities since the time-delay in
seeking medical attention had no significant role in disease progression. As a matter of fact, in
Africa, time-delay was seen as a marker of accessibility to medical care and, in fact, some stud-
ies compare time-lapse before and after interventional politics on health care improvement. In
West Africa, studies reported a time-delay between 42 [38] and 84 days [44,49], taking into
consideration all clinical forms. Specifically, a Beninese study reported distinct clinical forms
relating to time-lapse since first symptoms were remembered [28]. Time-delay was shorter for
non-ulcerated clinical forms (median 30 to 46 days), than for ulcerated forms (median 61
days) and larger for osteomyelitis (median 91 days).
In Australian studies, time-lapse until medical care was reported to be much shorter—
between 14 days (IQR 0–6 weeks) [40] and 42 days (ranging from 2 and 270 days) [50]. In this
distinct health-care reality, determinants for delay in seeking medical care were related to atyp-
ical sites of lesions, associated with an increased complexity in medical BU diagnosis. Interest-
ingly, in Australian patients, ulcerated versus non-ulcerated clinical forms did not experience
significantly different time lapses. Moreover, independently of the advances in diagnosis and
clinical management, there was no variation in time-delay between 1998–2004 and 2005–2011.
In Southern America, the time-delay reported among Peruvian BU patients was between 1
and 8 months [51].
Overall, our observations in a cohort of laboratory-confirmed cases of BU, strengthening
previous observations and show that the time-delay in seeking medical care is related to the
more advanced ulcerative forms, further justifying early diagnosis and treatment. Notably, we
additionally show that time-delay was not significantly associated with more severe phenotypes
Table 4. Multivariate analysis of the effect of time-delay on clinical BU forms in 476 laboratory-confirmed BU treated patients at CDTUB—Allada
from 2005 to 2013 (binary logistic regression).
Coeff. (SE) Odds Ratio (CI) (days) Odds Ratio (CI) (months) p-value
Male
Age 0.006 0.973 (0.961–0.985) 0.0001
Time delay a 0.001 1.000 (0.999–1.001) 0.999 (0.966–1.034) 0.799
Upper body lesions b
Age 0.006 0.987 (0.975–0.999) 0.028
Gender 0.192 0.837 (0.574–1.218) 0.352
Time delay 0.001 0.999 (0.998–1.001) 0.980 (0.945–1.017) 0.299
Ulcerative lesions
Age 0.006 1.002 (0.989–1.014) 0.793
Gender 0.204 1.067 (0.709–1.576) 0.786
Time delay 0.001 1.002 (1.000–1.004) 1.065 (1.005–1.129) 0.025
a time delay until seeking medical care; odds ratio for days and months
b upper body lesions: head + neck + upper limbs + thorax + abdomen
doi:10.1371/journal.pntd.0004005.t004
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Fig 6. Time-delay to seekmedical care related to severe BU forms. (A) multifocality (multifocal vs.
unifocal lesions); (B) lesion size (15cm vs. >15cm); (C) WHOCategory (Category 3 vs. category 1+2).
Circles represent the outliers and asterisks represent the extreme outliers. Statistical significance was
calculated using Welch's t-test. Differences with a p-value of0.05 were considered significant.
doi:10.1371/journal.pntd.0004005.g006
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of BU, such as multifocal lesions, larger lesions or WHO category 3 lesions. Indeed, our results
demonstrate that after initial progression lesions become stable regarding size and focal/multi-
focal progression. Therefore, in future studies on BU epidemiology, severe clinical forms
should be systematically considered as distinct phenotypes of the same disease and therefore
subjected to specific risk factor investigation. These results further highlight that intrinsic regu-
latory mechanisms, such as the host immune response and local biochemical and physical fac-
tors, most likely have relevant roles in determining severe phenotypes, justifying more
structural immune-related and bacterial genetic studies.
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Table 5. Multivariate analysis of the effect of time-delay on severe BU forms in 476 laboratory-confirmed BU treated patients at CDTUB—Allada
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Coeff. (SE) Odds Ratio (CI) (days) Odds Ratio (CI) (months) p-value
Multifocal lesions
Age 0.013 1.009 (0.984–1.034) 0.48
Gender 0.452 1.203 (0.496–2.918) 0.68
Time delay a 0.001 1.001 (0.999–1.003) 1.032 (0.978–1.089) 0.26
Larger lesions (>15 cm)
Age 0.006 1.004 (0.992–1.016) 0.536
Gender 0.211 1.462 (0.967–2.208) 0.071
Time delay 0.001 1.000 (0.999–1.001) 0.980 (0.945–1.017) 0.925
WHO category 3
Age 0.006 1.003 (0.991–1.015) 0.652
Gender 0.203 1.429 (0.960–2.128) 0.079
Time delay 0.001 1.001 (1.000–1.002) 1.020 (0.961–1.035) 0.247
a time delay until seeking medical care; odds ratio for days and months
doi:10.1371/journal.pntd.0004005.t005
Table 6. Multivariate analysis of the effect of time-delay on severe BU forms in 476 laboratory-con-
firmed BU treated patients at CDTUB—Allada from 2005 to 2013 (linear model regression).
B and 95%CI p-value
Lesion Size
Age 0.001 (-0.070–0.072) 0.977
Gender 1.369 (-0.867–3.605) 0.229
Time delay a (-)0.002 (-0.009–0.005) 0.598
Category 1, 2 and 3 (WHO)
Age 0.001 (-0.002–0.003) 0.657
Gender 0.079 (-0.009–0.166) 0.079
Time delay 0.0001 (0.0001–0.0001) 0.244
a time delay until seeking medical care; odds ratio for days and months
doi:10.1371/journal.pntd.0004005.t006
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